Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1455-1460

  Sean, P Tan ^a   Chouaid, Christos ^a,b,c   Hettler, D ^d   Baud, M ^a   Hejblum, G ^a,b,c   Tilleul, P ^a,e  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Pegfilgrastim; Quality of life; Small cell lung cancer; Willingness to pay

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSAGE FORM COMPARISON; FEBRILE NEUTROPENIA; FEMALE; HEALTH SURVEY; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; QUALITY OF LIFE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST OF ILLNESS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, ECONOMIC; NEUTROPENIA; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SOCIOECONOMIC FACTORS;

EID: 67649447003     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902918156     Document Type: Article

References (27)

1. Mughal T. Current and future use of hematopoietic growth factors in cancer medicine. Hematol Oncol 2004;22:121-134 (Pubitemid 40990933)
2. Valley AW. New treatment options for managing chemotherapy-induced neutropenia. Am J Health Syst Pharm 2002; 59:S11-17 (Pubitemid 34887493)
3. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations of the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol 2006;24:3187-3205 (Pubitemid 46638957)
4. Crawford J. Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol 2003;14:6-7 (Pubitemid 36150252)
5. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35 (Pubitemid 36150255)
6. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731 (Pubitemid 34111380)
7. Standaert B, Goldstone J, Lu ZJ, et al. Economic analysis of filgrastim use for patients with acute myeloid leukemia in the UK: a comparison of collection methods of resource use data. Pharmacoeconomics 2002;20:665-674 (Pubitemid 34983370)
8. Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-Cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Ped Oncol 2000;34:92-96 (Pubitemid 30090471)
9. Berstein BJ, Blanchard LM. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients. Am J Health Syst Pharm 1999;56:1330-1333 (Pubitemid 29316096)
10. Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small cell lung cancer. J Clin Oncol 2006;24:2991-2997 (Pubitemid 46638931)
11. Haithcox S, R Ramnes C, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003;2:2 (Pubitemid 38783219)
12. O'Brien B, Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996;16:288-299
13. Gafni A. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decision making about health care programs. Med Care 1991;29:1246-1252
14. Fortner BV, Schwartzberg L, Tauer K, et al. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005l;13:522-528
15. Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer 2004; 4:22 (Pubitemid 38851351)
16. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increases risk of hospitalization? Oncology 2006;40:402-406
17. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-1924 (Pubitemid 40563265)
18. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266 (Pubitemid 43673249)
19. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6:441-445 (Pubitemid 33022215)
20. Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-494 (Pubitemid 38420536)
21. Adams JR. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol 2006;24:2975-2977 (Pubitemid 46638926)
22. Chouaid C, Molinier L, Combescure C, et al. Economic evaluation of the clinical management of lung cancer in France. Br J Cancer 2004;90:397-402
23. Klose T. The contingent valuation method in health care. Health Policy 1999;47:97-123 (Pubitemid 29241789)
24. Gafni A. Willingness to pay: what's in a name. Pharmacoeconomics 1998;14:465-470 (Pubitemid 28512060)
25. Olsen J. Aiding priority setting in health care: is there a role for the contingent valuation method? Health Econ 1997;6:603-612
26. Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 2004;22:375-387 (Pubitemid 38609814)
27. Aristides M, Chen J, Schulz M, et al. Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. Pharmacoeconomics 2002;20:775-784 (Pubitemid 35034445)